---
title: "Sinopharm Accord, Sinopharm Group unit, posts H1 net profit attributable to shareholders down 8.97% to RMB 606.2 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297300414.md"
description: "Sinopharm Accord, a subsidiary of Sinopharm Group, reported H1 2026 revenue of RMB 36.27 billion, a 1.44% decline. Net profit attributable to shareholders fell 8.97% to RMB 606.2 million, with basic EPS at RMB 0.99 compared to RMB 1.09 previously. Operating cash flow swung to an outflow of RMB 1.52 billion from a prior inflow. Total assets decreased by 1.89% to RMB 48.17 billion, while net assets rose 1.42% to RMB 18.87 billion as of end-June."
datetime: "2026-08-28T09:44:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297300414.md)
  - [en](https://longbridge.com/en/news/297300414.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297300414.md)
generator: "portal-rs"
---

# Sinopharm Accord, Sinopharm Group unit, posts H1 net profit attributable to shareholders down 8.97% to RMB 606.2 million

-   Sinopharm Accord, a subsidiary of Sinopharm Group Co. Ltd., posted 1H 2026 revenue of RMB 36.27 billion, down 1.44%. \* Net profit attributable to shareholders fell 8.97% to RMB 606.2 million; basic EPS was RMB 0.99 versus RMB 1.09. \* Operating cash flow swung to an outflow of RMB 1.52 billion from an inflow of RMB 15.07 million. \* End-June total assets were RMB 48.17 billion, down 1.89% from the start of the period; net assets rose 1.42% to RMB 18.87 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12304796), on August 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [000028.CN](https://longbridge.com/en/quote/000028.CN.md)
- [200028.CN](https://longbridge.com/en/quote/200028.CN.md)
- [01099.HK](https://longbridge.com/en/quote/01099.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Sinopharm Group Signs Three-Year Supply Purchase Agreement With CNPGC](https://longbridge.com/en/news/304858315.md)
- [Sinopharm Accord, Sinopharm Group subsidiary, posts H1 net profit RMB 606 million, down 8.97%](https://longbridge.com/en/news/296110219.md)
- [Sinopharm Accord Posts Steady Nine-Month Results but Strong Q3 Profit Rebound](https://longbridge.com/en/news/302436104.md)
- [M Stanley: SINOPHARM  3Q26 Results Reflect Continued Pressure on Domestic Industry](https://longbridge.com/en/news/303044955.md)
- [Sinopharm Group Nine-Month Net Profit Falls to RMB 8.08 Billion](https://longbridge.com/en/news/303002045.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**